Ibrutinib (PCI -32765)                                                                              PCYC- 1128- CA Amendment 2.0                           25 January 2019  
                           Final  
 
Pharmacyclics LLC   Proprietary and Confidential  Page 162 a. Vital signs will be assessed after the subject has been resting in the sitting position for at least 3 minutes.  
b. All assessments are to be performed prior to dosing unless otherwise specified.  
c. Continuous from the signing of ICF or 14 days prior to the first dose of study drug (whichever is greater) through 30 days after the last dose of study drug. 
d. AEs are reported from the time the subject signs the ICF until 30 days following last dose of study drug. All new malignant t umors are to be reported as AEs 
through Long Term Follow -up for OS. 
e. Cycle 1 Day 1 ONLY: Assessment of AEs for 2 hours post everolimus administration. At the discretion of the investigator, subject may leave clinic 2 hours 
post everolimus administration.  
f. At Screening, 12- lead ECGs will be recorded. Abnormalities noted at Screening should be included in the medical history. 
g. Hepatitis serologies evaluated by central laboratory. If hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody is positive, then PCR must be performed and must be negative prior to enrollment.  
h. Serum or urine pregnancy test will be required at Screening (within 3 days of Day 1) for women of childbearing potential. The test must be repeated prior to first dose if not performed within 3 days of C1D1. The test will be performed locally. 
i. Measurements of lesions using RECIST  1.1 criteria is required where CT/MRI was obtained.  
j. Predose and postdose PK and PDn samples will be collected per the schedule in Appendix 2. 
k. Predose PDn sample  will be collecte d on C1D1. 
l. Blood and urine samples for biomarkers will be collected  prior to dosing on Day1 for the fir st 3 cycles and then  Day 1of every 3rd cycle thereafter until 
RECIST 1.1 documented disease progression, CR or EOT.  
m. Archival tumor biopsy tissue will be collected when available or optional fresh tumor will be collected on consenting subject s at Screening and upon 
documented disease progression. Fresh tumor biopsy at Screening must be performed 7 days prior to enrollment.  
n. Subjects who are withdrawn for reasons other than RECIST 1.1 determined progression will continue to have normally scheduled c linical and radiological 
disease assessments (CT/MRI) until disease progression is documented, death, withdrawal of consent for further follow up, or lost to follow up, whichever 
occurs first  
o. Ever olimus 10 mg PO qd should be administered 6 hours (± 15 minutes)  after ibrutinib.  
 
  
IMBRUVICA® (ibrutinib ) Clinical Study Report #1 PCYC-1128-CA
Confidential 
Page 559 of 1076
Ibrutinib (PCI -32765)                                                                              PCYC- 1128- CA Amendment 2.0                           25 January 2019  
                           Final  
 
Pharmacyclics LLC   Proprietary and Confidential  Page 163 Appendix 2. C2D1: Pharmacokinetics  and Pharmacodynamics Sampling Schedule – Renal Cell Carcinoma (RCC) Cohort 1c 
Cycle  Study Day  Predose Time after ibrutinib Dosinga 
1 h ± 15 min 2 h ± 15 min 4 h ± 15 min 6 h ± 15 min 
2 1 Xb X X X X 
a. Record actual time of sample collection.  
b. PK and PDn s ample s collected 24 hours (± 2 hours) after previous ibrutinib dose and prior to ibrutinib dosing on Cycle 2 Day 1, which is also 
prior to everolimus administration since ibrutinib is dosed 6 hours before everolimus dosing. 
c. PK samples will be collected in all cohort 1 subjects for ibrutinib PK determination only.  
  
IMBRUVICA® (ibrutinib ) Clinical Study Report #1 PCYC-1128-CA
Confidential 
Page 560 of 1076
Ibrutinib (PCI -32765)                                                                              PCYC- 1128- CA Amendment 2.0                           25 January 2019  
                           Final  
 
Pharmacyclics LLC   Proprietary and Confidential  Page 165 a. Vital signs will be assessed after the subject has been resting in the sitting position for at least 3 minutes.  
b. All assessments are to be performed prior to dosing unless otherwise specified.  
c. Continuous from the signing of ICF or 14 days prior to the first dose of study drug (whichever is greater) through 30 days after the last dose of study drug. 
d. AEs are reported from the time the subject signs the ICF until 30 days following last dose of study drug. All new malignant tumors ar e to be reported as AEs 
through Long Term Follow-up for OS. 
e. Cycle 1 Day 1 ONLY: Assessment of AEs for 2 hours post paclitaxel infusion . At the discretion of the investigator, subject may leave clinic 2 hours post 
paclitaxel infusion. 
f. At Screening, 12- lead ECGs will be recorded.  Abnormalities noted at Screening should be included in the medical history. 
g. Hepatitis serologies evaluated by central laboratory.  If hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody is positive, then PCR 
must be performed and must be negative prior to enrollment.  
h. Serum or urine pregnancy test will be required at Screening (within 3 days of Day 1) for women of childbearing potential. The test must be repeated prior to 
first dose if not perfor med within 3 days of C1D1. The test will be performed locally.  
i. Measurements of lesions using RECIST 1.1 criteria is required where CT/MRI was obtained.  
j. Predose and postdose PK and PDn samples will be collected per the schedule in Appendix 4  
k. Predose PDn sample will be collected on C1D1. 
l. Blood and urine samples for biomarkers will be collected prior to dosing on Day1 for the first 3 cycles and then Day 1of ever y 3rd cycle th ereafter until 
RECIST 1.1 documented disease progression or CR and at EOT.  
m. Archival tumor biopsy tissue will be collected when available or optional fresh tumor will be collected on consenting subjects at Screening and upon 
documented disease progressio n. Fresh tumor biopsy at Screening must be performed 7 days prior to enrollment.  
n. Subjects who are withdrawn for reasons other than RECIST 1.1 determined progression will continue to have normally scheduled clinical and radiological 
disease assessments (CT/MRI) until disease progression is documented, death, withdrawal of consent for further follow up, or lost to follow up, w hichever 
occurs first . 
o. Paclitaxel 80 mg/m2 IV qweek infusion should start 30 minutes hours (± 5 minutes) after ibrutinib. 
  
IMBRUVICA® (ibrutinib ) Clinical Study Report #1 PCYC-1128-CA
Confidential 
Page 562 of 1076
Ibrutinib (PCI -32765)                           PCYC -1128- CA-Amendment 2.0 25 January 2019 
Final  
Pharmacyclics LLC   Proprietary and Confidential  Page 168 a. Vital signs will be assessed after the subject has been resting in the sitting position for at least 3 minutes.  
b. All assessments are to be performed prior to dosing unless otherwise specified.  
c. Continuous from the signing of ICF or 14 days prior to the first dose of study drug (whichever is greater) through 30 days after the last dose of 
study drug. 
d. AEs are reported from the time the subject signs the ICF until 30 days following last dose of study drug. All new malignant tumor s are to be 
reported as AEs through Long Term Follow-up for OS. 
e. Cycle 1 Day 1 ONLY: Assessment of AEs for 2 hours post docetaxel infusion. At the discretion of the investigator, subject may leave clinic 2 
hours post completion of docetaxel infusion. 
f. At Screening, 12- lead ECGs will be recorded. Abnormalities noted at Screening should be included in the medical history.  
g. Hepatitis serologies evaluated by central laboratory. If hepatitis B core antibody, hepatitis B surface antigen , or hepatitis C antibody is 
positive, then PCR must be performed and must be negative prior to enrollment.  
h. Serum or urine pregnancy test will be required at Screening (within 3 days of Day 1) for women of childbearing potential. The test must be 
repeated  prior to first dose if not performed within 3 days of C1D1. The test will be performed locally. 
i. Measurements of lesions using RECIST 1.1 criteria is required where CT/MRI was obtained.  
j. Predose and postdose PK and PDn samples will be collected per the schedule in Appendix 6. 
k. Predose PDn sample will be collected on C1D1. 
l. Blood and urine samples for biomarkers will be collected prior to dosing on Day1 for the first 3 cycles and then Day 1  of every 3rd cycle 
thereafter until RECIST 1.1 documented disease progression or CR and at EOT. 
m. Archival tumor biopsy tissue will be collected when available or optional fresh tumor will be collected on consenting subject s at Screening 
and upon documented disease progression. Fresh tumor biopsy at Screening must be performed 7 days prior to enrollment.  
n. Subjects who are withdrawn for reasons other than RECIST 1.1 determined progression will continue to have normally scheduled clinical and 
radiological disease assessments (CT/MRI) until disease progression is documented, death, withdrawal of consent for further f ollow up, or lost 
to follow up, whichever occurs first 
o. Docetaxel (75 mg/m2 IV q 3weeks)  infusion should start 30 m inutes  hours (± 5 minutes) after ibrutinib. 
  
IMBRUVICA® (ibrutinib ) Clinical Study Report #1 PCYC-1128-CA
Confidential 
Page 565 of 1076
Ibrutinib (PCI -32765)                           PCYC -1128- CA-Amendment 2.0 25 January 2019 
Final  
Pharmacyclics LLC   Proprietary and Confidential  Page 171 a. Vital signs will be assessed after the subject has been resting in the sitting position for at least 3 minutes.  
b. All assessments are to be performed prior to dosing unless otherwise specified. 
c. Continuous from the signing of ICF or 14 days prior to the first dose of study drug (whichever is greater) through 30 days af ter the last dose of 
study drug. 
d. AEs are reported from the time the subject s igns the ICF until 30 days following last dose of study drug. All new malignant tumors are to be 
reported as AEs through Long Term Follow-up for OS. 
e. Cycle 1 Day 1 ONLY: Assessment of AEs for 2 hours post cetuximab infusion. At the discretion of the investigator, subject may leave clinic 2 
hours post cetuximab infus ion. 
f. At Screening, 12- lead ECGs will be recorded. Abnormalities noted at Screening should be included in the medical history.  
g. Hepatitis serologies evaluated by central laboratory. If hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody is 
positive, then PCR must be performed and must be negative prior to enrollment.  
h. Serum or urine pregnancy test will be required at Screening (within 3 days of Day 1) for women of childbea ring potential. The test must be 
repeated prior to first dose if not performed within 3 days of C1D1. The test will be performed locally. 
i. Measurements of lesions using RE CIST 1.1 criteria is required where CT/MRI was obtained.  
j. Predose and postdose PK and P Dn samples will be collected per the schedule in Appendix 8.  
k. Predose PDn sample will be collected on C1D1. 
l. Blood and urine samples for biomarkers will be collected prior to dosing on Day1 for the first 3 cycles and then Day 1 of every 3rd cycle, 
thereafter until RECIST 1.1 documented disease progression or CR and at EOT.  
m. Archival tumor biopsy tissue will be collected when available or optional fresh tumor will be collected on consenting subjects at Screening 
and upon documented disease progression. Fresh tumor biopsy at Screening must be performed 7 days prior to enrollment.  
n. Subjects who are withdrawn for reasons other than RECIST 1.1 determined progression will continue to have normally scheduled clinical and 
radiological disease assessments (CT/MRI) until disease progression is documented, death, withdrawal of consent for further f ollow up, or lost 
to follow up, whichever occurs first. 
o. Cetuximab  (C1D1 - 400 mg/m2 over120- minutes; after that- 250 mg/m2 over 60 minutes) infusion should start 30 minutes hours (± 5 minutes) 
after ibrutinib . 
p. CEA will be collected at Screening, prior to dosing on Day1 for the first 3 cycles and then Day 1of every 3rd cycle thereafte r unti l RECIST 
1.1 documented disease progression or CR and at EOT. 
  
IMBRUVICA® (ibrutinib ) Clinical Study Report #1 PCYC-1128-CA
Confidential 
Page 568 of 1076
Ibrutinib (PCI -32765)                           PCYC -1128- CA-Amendment 2.0 25 January 2019 
Final  
Pharmacyclics LLC   Proprietary and Confidential  Page 172 Appendix 8. C2D1: Pharmacokinetics and Pharmacodynamics Sampling Schedule – Colorectal Adenocarcinoma (CRC)  - 
Cohort 4c 
 
Cycle  Study Day  Predose Time after ibrutinib Dosinga 
1h ± 15 min 2 h ± 15 min 4 h ± 15 min 6 h ± 15 min 
2 1 Xb X X X X 
a. Record actual time of sample collection.  
b. PK and PDn samples collected 24 hours (± 2 hours) after previous ibrutinib dose and prior to ibrutinib dosing on Cycle 2 Day 1. 
PK samples will be collected in all cohort 4 subjects for ibrutinib PK determination only. 
  
IMBRUVICA® (ibrutinib ) Clinical Study Report #1 PCYC-1128-CA
Confidential 
Page 569 of 1076
Ibrutinib (PCI -32765)                           PCYC -1128- CA-Amendment 2.0 25 January 2019 
Final  
Pharmacyclics LLC   Proprietary and Confidential  Page 173 Appendix 9.  Schedule of Assessments – Urothelial Carcinoma – I brutinib Single Agent – Cohort 5 
Urothelial Carcinoma   Screening 
Phase  Treatment Phaseb FU Phase  
Cycle 1  Cycle 2  Cycle 3 through 
Treatment d/c  Efficacy 
Evaluations  EOT  Long -term FU  
D-3 OR 
Earlier  D1 D8 D15 D1 D8 D15 D1 Every 6 
weeks  30 days after 
treatment d/c  Every  
4 weeks  
Visit Window  -28 days   N/A ±2d ±2d ±2d ±2d  ±2d ±2d ±7d ±7d ±7d 
Informed consent  X                   
Confirmation of eligibility criteria  X                   
Medical history  X                   
Physical examination (including disease -related symptom 
assessment)  X  X  X X   X X   X   
Weight  X  X X X X X X X   X   
Vital Signsa X  X X X X X X X   X   
ECOG Performance Status  X  X  X X   X X   X   
KPS score  X                   
Concomitant medicationsc X  X X X X X X X   X   
AEsd X  X X X X X X X   X   
12-lead ECGf X                   
Laboratory                      
Hematology  X  X X X X X X X   X   
Serum Chemistry  X  X X X X X X X   X   
Coagulation panel  X                   
Hepatitis serologiesg X                   
Creatinine clearance (Cockcroft -Gault)  X                   
CRPo   Xo   Xo   Xo    
Urinalysis  X  X X X X X X X   X   
Pregnancy Testh X  Xh                 
Disease Assessment                      
CT / MRI scani Xi             Xi Xi   
Pharmacokinetics/Biomarkers                      
Pharmacokinetics (PK)j       Xj             
Molecular markers – bloodk     X   X     Xk    X   
Molecular markers - urinek     X   X     Xk   X   
Buccal Swab     X                 
Tumor biopsyl, m, n Xl Xm          Xn       
Study Drug Administration                      
In-clinic administration of ibrutinib     X X X X X X         
Dispense ibrutinib     X   X     X     
Study drug compliance review     X X X X X X X    X   
Survival and subsequent anticancer therapy                  X X 
IMBRUVICA® (ibrutinib ) Clinical Study Report #1 PCYC-1128-CA
Confidential 
Page 570 of 1076
Ibrutinib (PCI -32765)                           PCYC -1128- CA-Amendment 2.0 25 January 2019 
Final  
Pharmacyclics LLC   Proprietary and Confidential  Page 174  
a. Vital signs will be assessed after the subject has been resting in the sitting position for at least 3 minutes.  
b. All assessments are to be performed prior to dosing unless otherwise specified.  
c. Continuous from the signing of ICF or 14 days prior to the first dose of study drug (whichever is greater) through 30 days af ter the last dose 
of study drug.  
d. AEs are reported from the time the subject signs the ICF until 30 days following last dose of study drug. All new malignant tumors are to be 
reported as AEs through Long Term Follow-up for OS. 
f. At Screening, 12- lead ECGs will be recorded. Abnormalities noted at Screening should be included in the medical history. 
g. Hepatitis serologies evaluated by central laboratory. If hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody is 
positive, then PCR must be performed and must be negative prior to enrollment.  
h. Serum or urine pregnancy test will be required at Screening (within 3 days of Day 1) for women of childbearing potential. The test must be 
repeated prior to first dose if not performed within 3 days of C1D1. The test will be performed locally. 
i. Measurements of lesions using RECIST 1.1 criteria is required where CT/MRI was obtained.  
j. Predose and postdose ibrutinib PK samples will be collected per the schedule in Appendix 10  
k. Blood and urine samples for biomarkers will be collected prior to dosing on Day1 for the first 3 cycles and then Day 1 of every 3rd cycle 
thereafter until RECIST 1.1 documented disease progression or CR and at EOT. 
l. Archival tumor biopsy tissue will be collected when available or optional fresh tumor will be collected on consenting subject s at Screening 
and upon documented disease progression. Fresh tumor biopsy at Screening must be performed 7 days prior to enrollment. 
m. Applies to subjects enrolled in the paired-biopsy subgroup only. Pre- treatment fresh  tumor biopsy for 5-10 subjects. Cycle 1 dosing should 
be after ~3 days post biopsy. 
n. Applies to subjects enrolled in the paired-biopsy subgroup only. On- treatment fresh tumor biopsy should be collected during Cycle 3 
anytime from Cycle 3 Day 1 and prior to Cycle 4 Day 1. 
o. C- Reactive Protein will be collected on Day 1 of all cycles.  
  
IMBRUVICA® (ibrutinib ) Clinical Study Report #1 PCYC-1128-CA
Confidential 
Page 571 of 1076
Ibrutinib (PCI -32765)                           PCYC -1128- CA-Amendment 2.0 25 January 2019 
Final  
Pharmacyclics LLC   Proprietary and Confidential  Page 175 Appendix 10. C2D1: Pharmacokinetics Sampling Schedule and Scheme – Urothelial Carcinoma (Cohort 5) 
Study Cycle & Day  Time Points  brutinib (Cohort 5)  
Cycle 2  Day 1  Predose a X 
Drug Administration  Drug Administration  
1.0 hr post dose (±15 min)  X 
2.0 hr post dose (±15 min)  X 
4.0 hr post dose (±15 min)  X 
6.0 hr post dose (±15 min)  X 
 
a. Predose samples should be collected prior to the administration of any drug.  
 
  
IMBRUVICA® (ibrutinib ) Clinical Study Report #1 PCYC-1128-CA
Confidential 
Page 572 of 1076